Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sawai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sawai's Japan sales performance.

Immuno-oncology in 2019: the rapid evolution continues

Immuno-oncology in 2019: the rapid evolution continues

BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro The drug is also under regulatory review for this indication in the US and Japan, and the new use could help AZ compete in the market with SGLT2 rivals Invokana (canagliflozin)

Unlocking the potential of science and technology in the UK

Unlocking the potential of science and technology in the UK The context here is worth keeping in mind. According to World Bank figures, Korea (4.2%), Japan (3.3%), the United States (2.8%), Germany (2.8%), Switzerland (2.4%), France

Evenity back on track with FDA panel blessing in osteoporosis

Evenity back on track with FDA panel blessing in osteoporosis Amgen has already secured its first marketing approval for Evenity (romosozumab) – in Japan earlier this month – and with US approval seemingly assured now has the successor it needs for its $2bn ... Amgen and UCB are co-developing Evenity worldwide,

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B Suzhou Alphamab is already testing its PD-L1 inhibitor antibody KN035 in a number of clinical trials across tumour types in the US, China and Japan, but has licensed rights for

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics